IPCA Laboratories Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1571.75 -1.35 (-0.09%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1555.95
Today’s High
1586.8
52 Week Low
1042
52 Week High
1708.7
1573.55 -0.95 (-0.06%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1554.4
Today’s High
1587.5
52 Week Low
1041
52 Week High
1708.65
Key Metrics
- Market Cap (In Cr) 39945.73
- Beta 0.37
- Div. Yield (%) 0.25
- P/B 6.31
- TTM P/E 57.47
- Peg Ratio -2.78
- Sector P/E 31.15
- D/E 0.18
- Open Price 1571.75
- Prev Close 1573.1
IPCA Laboratories Analysis
Price Analysis
-
1 Week2.82%
-
3 Months13.74%
-
6 Month20.47%
-
YTD41.45%
-
1 Year48.43%
Risk Meter
- 28% Low risk
- 28% Moderate risk
- 28% Balanced Risk
- 28% High risk
- 28% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 3
- 3
- 2
- Buy
- 5
- 4
- 3
- 4
- Hold
- 2
- 2
- 2
- 2
- Sell
- 2
- 3
- 4
- 4
- Strong Sell
- 0
- 0
- 0
- 2
- Total
- 12
- 12
- 12
- 14
IPCA Laboratories News
Sagar Doshi of Nuvama recommends these 3 stocks to buy tomorrow - November 21
1 min read . 20 Nov 2024Stocks to buy: These 6 stocks may rise 5-10% in the next 3-4 weeks, say analysts
5 min read . 04 Nov 2024IPCA Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 7705.04
- Selling/ General/ Admin Expenses Total
- 1708.43
- Depreciation/ Amortization
- 357.24
- Other Operating Expenses Total
- 2099.7
- Total Operating Expense
- 6916.88
- Operating Income
- 788.16
- Net Income Before Taxes
- 842.67
- Net Income
- 547.35
- Diluted Normalized EPS
- 25.84
- Period
- 2024
- Total Assets
- 11101.28
- Total Liabilities
- 4769.09
- Total Equity
- 6332.19
- Tangible Book Valueper Share Common Eq
- 240.4
- Period
- 2024
- Cashfrom Operating Activities
- 1021.15
- Cashfrom Investing Activities
- -1291.79
- Cashfrom Financing Activities
- -552.55
- Net Changein Cash
- -823.19
- Period
- 2023
- Total Revenue
- 6244.32
- Selling/ General/ Admin Expenses Total
- 2474.11
- Depreciation/ Amortization
- 261.56
- Other Operating Expenses Total
- 31.65
- Total Operating Expense
- 5544.76
- Operating Income
- 699.56
- Net Income Before Taxes
- 745.29
- Net Income
- 471.32
- Diluted Normalized EPS
- 18.23
- Period
- 2023
- Total Assets
- 8626.43
- Total Liabilities
- 2784.41
- Total Equity
- 5842.02
- Tangible Book Valueper Share Common Eq
- 222.49
- Period
- 2023
- Cashfrom Operating Activities
- 805.81
- Cashfrom Investing Activities
- -725
- Cashfrom Financing Activities
- 507.24
- Net Changein Cash
- 588.05
- Period
- 2022
- Total Revenue
- 5829.79
- Selling/ General/ Admin Expenses Total
- 2092.32
- Depreciation/ Amortization
- 232.42
- Other Operating Expenses Total
- 23.76
- Total Operating Expense
- 4771.44
- Operating Income
- 1058.35
- Net Income Before Taxes
- 1114.56
- Net Income
- 884.08
- Diluted Normalized EPS
- 35.21
- Period
- 2022
- Total Assets
- 7623.53
- Total Liabilities
- 2158.69
- Total Equity
- 5464.84
- Tangible Book Valueper Share Common Eq
- 207.28
- Period
- 2022
- Cashfrom Operating Activities
- 860.16
- Cashfrom Investing Activities
- -855.05
- Cashfrom Financing Activities
- 426.81
- Net Changein Cash
- 431.92
- Period
- 2021
- Total Revenue
- 5419.99
- Selling/ General/ Admin Expenses Total
- 1788.86
- Depreciation/ Amortization
- 209.17
- Other Operating Expenses Total
- 19.79
- Total Operating Expense
- 4122.44
- Operating Income
- 1297.55
- Net Income Before Taxes
- 1381.28
- Net Income
- 1140.01
- Diluted Normalized EPS
- 45.7
- Period
- 2021
- Total Assets
- 6068.36
- Total Liabilities
- 1366.71
- Total Equity
- 4701.65
- Tangible Book Valueper Share Common Eq
- 178.98
- Period
- 2021
- Cashfrom Operating Activities
- 1090.13
- Cashfrom Investing Activities
- -520.69
- Cashfrom Financing Activities
- -305.82
- Net Changein Cash
- 263.62
- Period
- 2020
- Total Revenue
- 4648.71
- Selling/ General/ Admin Expenses Total
- 1713.32
- Depreciation/ Amortization
- 210.5
- Other Operating Expenses Total
- 12.81
- Total Operating Expense
- 3935.39
- Operating Income
- 713.32
- Net Income Before Taxes
- 738.89
- Net Income
- 606.32
- Diluted Normalized EPS
- 24.66
- Period
- 2020
- Total Assets
- 5259.83
- Total Liabilities
- 1632.35
- Total Equity
- 3627.48
- Tangible Book Valueper Share Common Eq
- 135.68
- Period
- 2020
- Cashfrom Operating Activities
- 564.58
- Cashfrom Investing Activities
- -509.65
- Cashfrom Financing Activities
- -130.46
- Net Changein Cash
- -75.53
- Period
- 2019
- Total Revenue
- 3773.18
- Selling/ General/ Admin Expenses Total
- 1533.82
- Depreciation/ Amortization
- 182.42
- Other Operating Expenses Total
- 12.16
- Total Operating Expense
- 3243.51
- Operating Income
- 529.67
- Net Income Before Taxes
- 546.46
- Net Income
- 444.83
- Diluted Normalized EPS
- 17.65
- Period
- 2019
- Total Assets
- 4550.67
- Total Liabilities
- 1428.28
- Total Equity
- 3122.39
- Tangible Book Valueper Share Common Eq
- 114.69
- Period
- 2019
- Cashfrom Operating Activities
- 492.28
- Cashfrom Investing Activities
- -156.31
- Cashfrom Financing Activities
- -183.2
- Net Changein Cash
- 152.77
- Period
- 2018
- Total Revenue
- 3283.57
- Selling/ General/ Admin Expenses Total
- 1425.58
- Depreciation/ Amortization
- 177.73
- Other Operating Expenses Total
- 12.23
- Total Operating Expense
- 3006.1
- Operating Income
- 277.47
- Net Income Before Taxes
- 290.53
- Net Income
- 239.42
- Diluted Normalized EPS
- 9.5
- Period
- 2018
- Total Assets
- 4117.3
- Total Liabilities
- 1428.73
- Total Equity
- 2688.57
- Tangible Book Valueper Share Common Eq
- 101.35
- Period
- 2018
- Cashfrom Operating Activities
- 341.13
- Cashfrom Investing Activities
- -135.4
- Cashfrom Financing Activities
- -130.41
- Net Changein Cash
- 75.32
- Period
- 2024-09-30
- Total Revenue
- 2354.9
- Selling/ General/ Admin Expenses Total
- 509.84
- Depreciation/ Amortization
- 100.35
- Other Operating Expenses Total
- 645.02
- Total Operating Expense
- 2013.77
- Operating Income
- 341.13
- Net Income Before Taxes
- 344.83
- Net Income
- 229.48
- Diluted Normalized EPS
- 9.05
- Period
- 2024-09-30
- Total Assets
- 11423.77
- Total Liabilities
- 4723.38
- Total Equity
- 6700.39
- Tangible Book Valueper Share Common Eq
- 254.99
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 739.59
- Cashfrom Investing Activities
- -300.8
- Cashfrom Financing Activities
- -336.34
- Net Changein Cash
- 102.45
- Period
- 2024-06-30
- Total Revenue
- 2092.63
- Selling/ General/ Admin Expenses Total
- 487.87
- Depreciation/ Amortization
- 98.89
- Other Operating Expenses Total
- 568.55
- Total Operating Expense
- 1798.8
- Operating Income
- 293.83
- Net Income Before Taxes
- 290.39
- Net Income
- 192.24
- Diluted Normalized EPS
- 7.58
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2033.01
- Selling/ General/ Admin Expenses Total
- 466.01
- Depreciation/ Amortization
- 98.13
- Other Operating Expenses Total
- 559.21
- Total Operating Expense
- 1945.96
- Operating Income
- 87.05
- Net Income Before Taxes
- 76.6
- Net Income
- 59.59
- Diluted Normalized EPS
- 5.85
- Period
- 2024-03-31
- Total Assets
- 11101.28
- Total Liabilities
- 4769.09
- Total Equity
- 6332.19
- Tangible Book Valueper Share Common Eq
- 240.4
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1021.15
- Cashfrom Investing Activities
- -1291.79
- Cashfrom Financing Activities
- -552.55
- Net Changein Cash
- -823.19
- Period
- 2023-12-31
- Total Revenue
- 2052.86
- Selling/ General/ Admin Expenses Total
- 459.04
- Depreciation/ Amortization
- 99.5
- Other Operating Expenses Total
- 565.54
- Total Operating Expense
- 1821.03
- Operating Income
- 231.83
- Net Income Before Taxes
- 288.89
- Net Income
- 179.88
- Diluted Normalized EPS
- 6.99
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 2033.96
- Selling/ General/ Admin Expenses Total
- 425.87
- Depreciation/ Amortization
- 90.34
- Other Operating Expenses Total
- 609.24
- Total Operating Expense
- 1803.03
- Operating Income
- 230.93
- Net Income Before Taxes
- 225.36
- Net Income
- 145.06
- Diluted Normalized EPS
- 5.72
- Period
- 2023-09-30
- Total Assets
- 11383.8
- Total Liabilities
- 5235.07
- Total Equity
- 6148.73
- Tangible Book Valueper Share Common Eq
- 232.64
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 319.35
- Cashfrom Investing Activities
- -1164.73
- Cashfrom Financing Activities
- 131.23
- Net Changein Cash
- -714.15
- Period
- 2023-06-30
- Total Revenue
- 1587.58
- Selling/ General/ Admin Expenses Total
- 357.51
- Depreciation/ Amortization
- 69.27
- Other Operating Expenses Total
- 407.12
- Total Operating Expense
- 1349.23
- Operating Income
- 238.35
- Net Income Before Taxes
- 251.82
- Net Income
- 162.82
- Diluted Normalized EPS
- 6.42
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 1511.63
- Selling/ General/ Admin Expenses Total
- 327.33
- Depreciation/ Amortization
- 69.54
- Other Operating Expenses Total
- 412.08
- Total Operating Expense
- 1400.13
- Operating Income
- 111.5
- Net Income Before Taxes
- 129.44
- Net Income
- 76.52
- Diluted Normalized EPS
- 3.02
- Period
- 2023-03-31
- Total Assets
- 8626.43
- Total Liabilities
- 2784.41
- Total Equity
- 5842.02
- Tangible Book Valueper Share Common Eq
- 222.49
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 805.81
- Cashfrom Investing Activities
- -725
- Cashfrom Financing Activities
- 507.24
- Net Changein Cash
- 588.05
- Period
- 2022-12-31
- Total Revenue
- 1546
- Selling/ General/ Admin Expenses Total
- 318.44
- Depreciation/ Amortization
- 66.57
- Other Operating Expenses Total
- 449.87
- Total Operating Expense
- 1396.71
- Operating Income
- 149.29
- Net Income Before Taxes
- 169.34
- Net Income
- 107.84
- Diluted Normalized EPS
- 4.25
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
IPCA Laboratories Technical
Moving Average
SMA
- 5 Day1540.12
- 10 Day1558.25
- 20 Day1572.35
- 50 Day1537.67
- 100 Day1407.17
- 300 Day1317.49
IPCA Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Glenmark Pharmaceuticals
- 1464.9
- -27.45
- -1.84
- 1830.05
- 761.15
- 41338.01
- Glaxosmithkline Pharmaceuticals
- 2376.5
- -59.75
- -2.45
- 3073.87
- 1557.92
- 40259.34
- IPCA Laboratories
- 1571.75
- -1.35
- -0.09
- 1708.7
- 1042
- 39875.3
- Biocon
- 323.15
- -3.95
- -1.21
- 395.65
- 231.35
- 38797.39
- Ajanta Pharmaceuticals
- 2938.1
- -1.55
- -0.05
- 3485.75
- 1852.55
- 36994.99
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Glenmark Pharmaceuticals
- -
- 5.37
- 1.61
- 1.43
- Glaxosmithkline Pharmaceuticals
- 59.59
- 23.23
- 20.45
- 12.25
- IPCA Laboratories
- 60.9
- 6.31
- 14.98
- 12.25
- Biocon
- 41.47
- 1.98
- 6.82
- 9.37
- Ajanta Pharmaceuticals
- 45.16
- 10.36
- 21.37
- 19.31
IPCA Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-Nov-24
- Quarterly Results & Interim Dividend
- 30-Sept-24
- Others
- 13-Aug-24
- Quarterly Results
- 29-May-24
- Audited Results & Final Dividend
- 14-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results & Interim Dividend
- 10-Aug-23
- Quarterly Results
- 29-May-23
- Audited Results
- 14-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 13-Aug-24
- 18-Jul-24
- AGM
- 30-Mar-24
- 23-Feb-24
- POM
- 10-Aug-23
- 29-May-23
- AGM
- 31-Mar-23
- 24-Feb-23
- POM
- 02-Sept-21
- 04-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 24-Oct-24
- 25-Nov-24
- 25-Nov-24
- 2
- 29-May-24
- -
- 06-Aug-24
- 2
- 26-Oct-23
- 22-Nov-23
- 22-Nov-23
- 2
- 02-Nov-22
- 23-Nov-22
- 22-Nov-22
- 4
- 20-Oct-21
- 23-Nov-21
- 22-Nov-21
- 8
- Ex-Splits
- Old FV
- New FV
- Description
- 10-Jan-22
- 2
- 1
- Stock split from Rs. 2/- to Re. 1/-.